Moreover, GRP78 has been implicated in castration-resistant prostate cancer, where it sustains androgen receptor activity even in the absence of androgens, allowing cancer cells to bypass hormone deprivation therapy. This evidence concerns the gene HSPA5 and Familial prostate cancer.